Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
VEGF
Biotech
BMS inks $11B biobucks BioNTech deal to join bispecific rush
The deal, which features up to $7.6 billion in milestones, gives BMS a 50% stake in one of the leading assets in the hottest area of immuno-oncology.
Nick Paul Taylor
Jun 2, 2025 8:59am
Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific
May 20, 2025 4:47am
Kodiak resurrects eye drug after ph. 3 data renew approval plans
Nov 6, 2023 8:40am
Clean up on IL-2: Moderna mops up autoimmune asset
Aug 3, 2022 10:59am
Could a glaucoma drug also fight obesity?
Aug 10, 2018 10:25am
